Evidence map›Paper›PMID 35431953›Full record

ArticleFrontiers in pharmacology2022

Absorption, Metabolism, and Excretion of ACT-1004-1239, a First-In-Class CXCR7 Antagonist:

Christine Huynh, Swen Seeland, Jerome Segrestaa, Carmela Gnerre, Jens Hogeback, Henriette E Meyer Zu Schwabedissen, Jasper Dingemanse, Patricia N Sidharta

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Christine HuynhDepartment of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland.
Swen SeelandDepartment of Preclinical Drug Metabolism and Pharmacokinetics, Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland.
Jerome SegrestaaDepartment of Preclinical Drug Metabolism and Pharmacokinetics, Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland.
Carmela GnerreDepartment of Preclinical Drug Metabolism and Pharmacokinetics, Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland.
Jens HogebackA&M Labor für Analytik und Metabolismusforschung Service GmbH, Bergheim, Germany.
Henriette E Meyer Zu SchwabedissenDepartment of Pharmaceutical Sciences, Biopharmacy, University of Basel, Basel, Switzerland.
Jasper DingemanseDepartment of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland.
Patricia N SidhartaDepartment of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland.
Idorsia (Switzerland) · CHUniversity of Basel · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ACT-1004-1239 is a potent, selective, first-in-class CXCR7 antagonist, which shows a favorable preclinical and clinical profile. Here we report the metabolites and the metabolic pathways of ACT-1004-1239 identified using results from

Indexed as

14C-ACT-1004-1239accelerator mass spectrometryADMECXCR7CYP3A4first-in-humanmicrotracer

Identifiers

PMID35431953
PMCPMC9006992
OpenAlexW4220983495

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.